Drug intelligence / Profile preview

ABT-751 + pemetrexed

Development stage: Unknown
Lead developer: Abbott
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

ABT-751 + pemetrexed is a combination therapy consisting of ABT-751, an oral antimitotic and vascular disrupting agent that binds to the colchicine site of β-tubulin and prevents microtubule polymerization, and pemetrexed, a standard chemotherapy agent. This combination was studied for the treatment of non-small cell lung cancer (NSCLC).

Targets

GART (GAR transformylase)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on ABT-751 + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABT-751 + pemetrexed.

Explore the full profile